Pfizer's TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting
[url="]Pfizer Inc. (NYSE: PFE)[/url] today announced that the U.S. Food and Drug Administration (FDA) has expanded approval of TALZENNAÂ (talazoparib) in combi